Announcements Trials
Browse Landscape

Phase

Phase 2 9Phase 1 2Phase 3 1Phase 2/3 1Phase 1/2 1

Status

Completed 5Terminated 2Recruiting 2Active not recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Stomach Neoplasms 1Liver Neoplasms 1Esophageal Neoplasms 1Carcinoma, Hepatocellular 1

Interventions

pembrolizumab 86Cyclophosphamide 75Nivolumab 55Specimen Handling 49fludarabine 48Magnetic Resonance Spectroscopy 44Carboplatin 41Biopsy 39Radiotherapy 32fludarabine phosphate 29Gemcitabine 28venetoclax 27atezolizumab 26Paclitaxel 26Ipilimumab 26Radiation 22Dexamethasone 22Cisplatin 22Radiosurgery 21durvalumab 20Rituximab 20Lenalidomide 19Temozolomide 17Bevacizumab 17Pemetrexed 15Decitabine 15Cytarabine 15130-nm albumin-bound paclitaxel 15palbociclib 14ibrutinib 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Active not recruiting × relatlimab × Clear all
NCT03044613 2026-03-23

Nivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1 Active not recruiting
32 enrolled
Gastrointestinal

Esophageal Neoplasms, Stomach Neoplasms

NCT04658147 2025-12-18

Feasibility and Efficacy of Perioperative Nivolumab With or Without Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma (HCC)

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1 Active not recruiting
31 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡